2,851
edits
Nicotinamide Mononucleotide (NMN): Difference between revisions
Nicotinamide Mononucleotide (NMN) (view source)
Revision as of 19:39, 2 November 2023
, 2 November 2023→Clinical Trials
| Line 143: | Line 143: | ||
!Outcome | !Outcome | ||
|- | |- | ||
|{{pmid_text | |{{pmid_text|31685720}} | ||
| | | | ||
* singe admission of up to 500 mg | * singe admission of up to 500 mg | ||
| Line 153: | Line 153: | ||
* admission was safe and well-tolerated | * admission was safe and well-tolerated | ||
|- | |- | ||
|{{pmid_text | |{{pmid_text|33888596}} | ||
|[[RCT]], 10 weeks | |[[RCT]], 10 weeks | ||
* placebo (n=12) | * placebo (n=12) | ||
| Line 165: | Line 165: | ||
* improvement in muscle insulin sensitivity is clinically relevant and is similar to the improvement observed after ~10% weight loss | * improvement in muscle insulin sensitivity is clinically relevant and is similar to the improvement observed after ~10% weight loss | ||
|- | |- | ||
|{{pmid_text | |{{pmid_text|34238308}} | ||
|[[RCT]], 6 weeks | |[[RCT]], 6 weeks | ||
* placebo (n=12) | * placebo (n=12) | ||
| Line 179: | Line 179: | ||
* The improvement is muscle, not cardiac, related. | * The improvement is muscle, not cardiac, related. | ||
|- | |- | ||
| {{pmid_text | | {{pmid_text|36002548}} | ||
|[[RCT]], 4 weeks | |[[RCT]], 4 weeks | ||
| Line 192: | Line 192: | ||
* Results indicate that NMN can be administered orally to humans at doses 1250 mg once daily for up to 4 weeks without causing hepatotoxicity and vasodilative flushing, and is believed to have a higher upper tolerable limit compared to NAM and NA. | * Results indicate that NMN can be administered orally to humans at doses 1250 mg once daily for up to 4 weeks without causing hepatotoxicity and vasodilative flushing, and is believed to have a higher upper tolerable limit compared to NAM and NA. | ||
|- | |- | ||
| {{pmid_text | | {{pmid_text|36482258}} | ||
|[[RCT]], 8.5 weeks (60 days) | |[[RCT]], 8.5 weeks (60 days) | ||
| Line 209: | Line 209: | ||
* 900 mg/day oral dose did not give significantly better efficacy than 600 mg/day dose | * 900 mg/day oral dose did not give significantly better efficacy than 600 mg/day dose | ||
|- | |- | ||
| {{pmid_text | | {{pmid_text|35215405}} | ||
|[[RCT]], 12 weeks | |[[RCT]], 12 weeks | ||